Richard A. Lerner Sells 7,000 Shares of Intra-Cellular Therapies Inc. (ITCI) Stock
Intra-Cellular Therapies Inc. (NASDAQ:ITCI) Director Richard A. Lerner sold 7,000 shares of Intra-Cellular Therapies stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $15.09, for a total transaction of $105,630.00. Following the sale, the director now owns 8,621 shares of the company’s stock, valued at $130,090.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) traded up $0.34 during mid-day trading on Friday, hitting $15.24. 1,550,509 shares of the company were exchanged, compared to its average volume of 412,263. Intra-Cellular Therapies Inc. has a 52-week low of $7.85 and a 52-week high of $22.67.
Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.53). The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.06 million. Intra-Cellular Therapies had a negative net margin of 28,038.35% and a negative return on equity of 27.40%. The business’s quarterly revenue was up 675.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.70) earnings per share. research analysts expect that Intra-Cellular Therapies Inc. will post -2.17 EPS for the current fiscal year.
ITCI has been the subject of a number of recent analyst reports. Cowen reiterated a “buy” rating and set a $20.00 price target on shares of Intra-Cellular Therapies in a research report on Wednesday, August 23rd. BTIG Research reiterated a “buy” rating and set a $36.00 price target on shares of Intra-Cellular Therapies in a research report on Friday, September 8th. SunTrust Banks upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research report on Wednesday, November 8th. Zacks Investment Research upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $17.00 price target for the company in a research report on Wednesday, November 8th. Finally, Canaccord Genuity initiated coverage on shares of Intra-Cellular Therapies in a research report on Friday. They set a “buy” rating and a $31.00 price target for the company. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company’s stock. Intra-Cellular Therapies has an average rating of “Buy” and a consensus price target of $25.67.
TRADEMARK VIOLATION NOTICE: “Richard A. Lerner Sells 7,000 Shares of Intra-Cellular Therapies Inc. (ITCI) Stock” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/12/16/richard-a-lerner-sells-7000-shares-of-intra-cellular-therapies-inc-itci-stock.html.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.